| Autor: |
Rigonato-Oliveira NC; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., de Brito AA; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., Vitoretti LB; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., de Cunha Moraes G; Heart Institute of Clinics Hospital, Medical School of the University of São Paulo (FMUSP), São Paulo, Brazil., Gonçalves T; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., Herculano KZ; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., Alves CE; Post-Graduate in Public Heath, University Nove de Julho (UNINOVE), São Paulo, Brazil., Lino-Dos-Santos-Franco A; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil., Aimbire F; Biotechnology and Translational Medicine, Federal University of São Paulo-UNIFESP, Sao José dos Campos, Brazil., Vieira RP; Universidade Brasil, Post-Graduation Program in Bioengineering and in Biomedical Engineering, Campus Itaquera, Rua Carolina Fonseca 235, São Paulo, SP 08230-030, Brazil.; Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology (IBEPIPE), Rua Pedro Ernesto 240, São José dos Campos, SP 12245-520, Brazil.; Federal University of São Paulo (UNIFESP), Post-Graduation Program in Sciences of Human Movement and Rehabilitation, Avenida Ana Costa 95, Santos, SP 11060-001, Brazil.; Anhembi Morumbi University, School of Medicine, Avenida Deputado Benedito Matarazo 4050, São José dos Campos, SP 12230-002, Brazil., Ligeiro de Oliveira AP; Post-Graduate Program in Biophotonics Applied to Health Sciences, University Nove de Julho (UNINOVE), Sao Paulo, Brazil. |
| Abstrakt: |
Asthma is characterized by chronic inflammation in the airways. Several models have been proposed for the discovery of new therapies. Low-Level Laser Therapy (LLLT) is relatively new and effective, very low cost, with no side effects. However, there is still no consensus on the optimal dose to be used. In this sense, the objective of the present study was to evaluate the best dose in an experimental model of asthma induced by House Dust Mite (HDM). Balb/c mice received administration of 100 ug/animal HDM and LLLT applications (diode laser: 660 nm, 100 mW and four different energies 1J, 3J, 5J, and 7.5J) for 16 days. After 24 hours, we studied inflammatory, functional, and structural parameters. The results showed that LBI was able to modulate the pulmonary inflammation observed by reducing the number of cells in Bronchoalveolar Lavage Fluid (BALF) as well as reducing the percentage of neutrophils, eosinophils and T lymphocytes. On the other hand, LLLT increased the level of IL-10 and reduced levels of IL-4, IL-5 and IL-13 in BALF. LLLT was able to reduce the production of mucus, peribronchial eosinophils, collagen deposition, bronchoconstriction index, and bronchial and muscular thickening in the airways. We concluded that the use of LLLT in the treatment of chronic inflammation of the airways attenuated the inflammatory process and functional and structural parameters. We emphasize, in general, that the 1J and 3J laser presented better results. Thus, photobiomodulation may be considered a promising tool for the treatment of chronic pulmonary allergic inflammation observed in asthma. |
